Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
April 20 2023 - 7:00AM
Business Wire
Eight Poster Presentations Include Results
from 12-Month Safety Extension Trial of Investigational Treatment
NOV03 (Perfluorohexyloctane), as well as Data on XIPERE®
(Triamcinolone Acetonide Injectable Suspension) for
Suprachoroidal Use
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a
leading global eye health company dedicated to helping people see
better to live better, today announced the presentation of eight
scientific poster presentations during the Association for Research
in Vision and Ophthalmology (ARVO) annual meeting, which will take
place in New Orleans from April 23-27, 2023.
The presentations include results from the 12-month KALAHARI
safety extension study of the investigational treatment NOV03
(perfluorohexyloctane), as well as the results of two studies on
surgical intraocular lens pipeline programs. Another presentation
will focus on the early adoption of XIPERE® (triamcinolone
acetonide injectable suspension) for suprachoroidal use by
providers, and two others will feature a data analysis from Bausch
+ Lomb’s Antibiotic Resistance Monitoring in Ocular micRoorganisms
(ARMOR) surveillance study.
“At this year’s ARVO meeting, scientists will present a variety
of clinical research on our Bausch + Lomb product portfolio,
pipeline programs and the latest results from our unique ARMOR
study, which for more than 10 years has tracked antibiotic
resistance patterns specific to pathogens that affect the eye,”
said Yehia Hashad, M.D., executive vice president, Research &
Development and chief medical officer, Bausch + Lomb. “Bausch +
Lomb will continue to remain focused on conducting research that
will help us develop new products and medicines to address the
evolving needs of customers and patients.”
Following is a complete list of titles and lead authors for each
of these posters:
- “Antibiotic Resistance Among Ocular Pathogens—an Update from
the 2022 ARMOR study.” Sanfilippo et al.
- “Comparative Evaluation of the Attributes of a New Cohesive
Ophthalmic Viscosurgical Device.” Hosten et al.
- “Early Adoption of Triamcinolone Acetonide Suprachoroidal
Injection for Uveitic Macular Edema: A Physician Survey.” Chang et
al.
- “Evaluation of Color Perception and Contrast Acuity of Novel UV
Light-Filtering Material for IOLs as Compared to Yellow-Tinted Blue
light Filtering lenses.” Kolesnitchenko et al.
- “Evaluation of Enhanced Monofocal Plus IOLs with Extended Depth
of Focus.” Lau et al.
- “Longitudinal Analysis of In Vitro Antibiotic Resistance Among
Ocular Staphylococci Collected in the ARMOR study.” Asbell et
al.
- “Long‐term Safety and Efficacy of NOV03 (Perfluorohexyloctane)
for the Treatment of Patients with Dry Eye Disease associated with
Meibomian Gland Dysfunction: The Kalahari Study.” Vittitow et
al.
- “Spectroscopic Characterization of Perfluorohexyloctane, an Eye
Drop for Dry Eye Disease.” Borchman et al.
Important Safety Information about XIPERE®
INDICATION XIPERE® (triamcinolone acetonide injectable
suspension) for suprachoroidal use is a corticosteroid indicated
for the treatment of macular edema associated with uveitis.
IMPORTANT SAFETY INFORMATION Patients should be monitored
following injection for elevated intraocular pressure. See Dosage
and Administration instructions in full Prescribing
Information.
- XIPERE is contraindicated in patients with active or
suspected ocular or periocular infections including most
viral diseases of the cornea and conjunctiva, including active
epithelial herpes simplex keratitis (dendritic keratitis),
vaccinia, varicella, mycobacterial infections, and fungal
diseases.
- XIPERE is contraindicated in patients with known
hypersensitivity to triamcinolone acetonide or any other
components of this product.
- Use of corticosteroids may produce cataracts, increased
intraocular pressure, and glaucoma. Use of corticosteroids may
enhance the establishment of secondary ocular infections due to
bacteria, fungi, or viruses, and should be used cautiously in
patients with a history of ocular herpes simplex.
- Hypothalamic-pituitary-adrenal (HPA) axis suppression,
Cushing’s syndrome, and hyperglycemia can occur following
administration of a corticosteroid. Monitor patients for these
conditions with chronic use.
- In controlled studies, the most common ocular adverse reactions
were increased ocular pressure, non-acute (14%), eye pain,
non-acute (12%), cataract (7%), increased intraocular pressure,
acute (6%), vitreous detachment (5%), injection site pain (4%),
conjunctival hemorrhage (4%), visual acuity reduced (4%), dry eye
(3%), eye pain, acute (3%), photophobia (3%), and vitreous floaters
(3%), and in 2% of patients: uveitis, conjunctival hyperaemia,
punctate keratitis, conjunctival oedema, meibomianitis, anterior
capsule contraction, chalazion, eye irritation, eye pruritus,
eyelid ptosis, photopsia, and vision blurred.
The most common non-ocular adverse event was headache (5%).
Corticosteroids should be used during pregnancy or nursing only
if the potential benefit justifies the potential risk to the fetus
or nursing infant.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb
at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit
www.fda.gov/medwatch.
Please click here for full Prescribing Information.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
Forward-looking Statements This news release may contain
forward-looking statements, which may generally be identified by
the use of the words “anticipates,” “hopes,” “expects,” “intends,”
“plans,” “should,” “could,” “would,” “may,” “believes,”
“estimates,” “potential,” “target,” or “continue” and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch + Lomb’s filings with
the U.S. Securities and Exchange Commission and the Canadian
Securities Administrators, which factors are incorporated herein by
reference. They also include, but are not limited to, risks and
uncertainties caused by or relating to the evolving COVID-19
pandemic, and the fear of that pandemic and its potential effects,
the severity, duration and future impact of which are highly
uncertain and cannot be predicted, and which may have a material
adverse impact on Bausch + Lomb, including but not limited to its
project development timelines, launches and costs (which may
increase). Readers are cautioned not to place undue reliance on any
of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. Bausch + Lomb
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this news release or to reflect actual outcomes, unless required by
law.
XIPERE® is a trademark of Clearside Biomedical, Inc. used under
license. © 2023 Bausch + Lomb. MTB.0116.USA.23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230420005177/en/
Investors: Arthur Shannon arthur.shannon@bausch.com
Allison Ryan allison.ryan@bausch.com (877) 354-3705 (toll free)
(908) 927-0735
Media: Lainie Keller lainie.keller@bausch.com (908)
927-1198
Kristy Marks kristy.marks@bausch.com (908) 927-0683
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024